New Additions to Drugs.com for 2014
The following 53 drugs were added to the Drugs.com database in 2014.
Namzaric
Dec 30, 2014 - Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) is an NMDA receptor antagonist and acetylcholinesterase inhibitor fixed-dose combination for the treatment of moderate to severe Alzheimer’s disease.
Saxenda
Dec 30, 2014 - Saxenda (liraglutide) is a once-daily glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity.
Opdivo
Dec 30, 2014 - Opdivo (nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody for the treatment of melanoma, non-small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, MSI-H or dMMR metastatic colorectal cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma, gastric cancer, and gastroesophageal junction cancer.
Soolantra
Dec 30, 2014 - Soolantra (ivermectin) is a topical antiparasitic with anti-inflammatory properties for the treatment of rosacea potentially caused by the microscopic skin mite Demodex folliculorum.
Viekira
Dec 30, 2014 - Viekira Pak (ombitasvir/paritaprevir/ritonavir with dasabuvir) is an NS5A inhibitor, NS3/4A
protease inhibitor and CYP3A inhibitor combination co-packaged with a non-nucleoside NS5B palm polymerase inhibitor for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection.
Lynparza
Dec 30, 2014 - Lynparza (olaparib) is a PARP inhibitor for the treatment of ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.
Hysingla ER
Dec 21, 2014 - Hysingla ER (hydrocodone) is a single-entity (without acetaminophen) extended-release opioid analgesic for around-the-clock management of moderate to severe chronic pain.
Xigduo XR
Nov 2, 2014 - Xigduo XR (dapagliflozin and metformin hydrochloride) is a once-daily sodium-glucose cotransporter 2 (SGLT2) inhibitor and biguanide combination for the treatment of type 2 diabetes.
Ofev
Oct 29, 2014 - Ofev (nintedanib) is a small molecule tyrosine kinase inhibitor (TKI) for the treatment of idiopathic pulmonary fibrosis, and systemic sclerosis-associated interstitial lung disease.
Esbriet
Oct 28, 2014 - Esbriet (pirfenidone) is a TGF-beta synthesis inhibitor for the treatment of patients with idiopathic pulmonary fibrosis (IPF).
Harvoni
Oct 28, 2014 - Harvoni (ledipasvir and sofosbuvir) is a once-daily NS5A inhibitor and nucleotide analog polymerase inhibitor fixed-dose combination for the treatment of chronic hepatitis C genotype 1 infection.
Akynzeo
Oct 23, 2014 - Akynzeo (netupitant and palonosetron) is an oral NK1 receptor antagonist and 5-HT3 receptor antagonist fixed-dose combination indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV).
Tybost
Oct 21, 2014 - Tybost (cobicistat) is a potent inhibitor of cytochrome P450 3A (CYP3A) which acts as a pharmacoenhancing or "boosting" agent for antiviral drugs used in the treatment of HIV infection.
Vitekta
Oct 14, 2014 - Vitekta (elvitegravir) is an integrase inhibitor for the combination treatment of HIV-1 infection in treatment-experienced adults.
Trulicity Pen
Sep 18, 2014 - Trulicity (dulaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes, and for cardiovascular risk reduction.
Movantik
Sep 17, 2014 - Movantik (naloxegol) is a peripherally-acting mu-opioid receptor antagonist indicated for the treatment of opioid-induced constipation.
Contrave
Sep 12, 2014 - Contrave (bupropion/naltrexone) is an aminoketone antidepressant and opioid antagonist combination indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management.
Keytruda
Sep 4, 2014 - Keytruda (pembrolizumab) is a type of immunotherapy that is given by intravenous (into a vein) infusion over 30 minutes to treat many different types of cancer such as melanoma, lung cancer, and some lymphomas. It may be used alone or in combination with other medicines, including chemotherapy.
Kabiven
Aug 27, 2014 - Kabiven (amino acids, electrolytes, dextrose
and lipid injectable emulsion) is indicated as a source of calories, protein, electrolytes and essential fatty acids for adult patients requiring parenteral nutrition.
Triumeq
Aug 26, 2014 - Triumeq (abacavir, dolutegravir and lamivudine) is a fixed-dose combination containing the INSTI dolutegravir and the NRTIs abacavir and lamivudine for the treatment of HIV-1 infection.
Arnuity Ellipta
Aug 24, 2014 - Arnuity Ellipta (fluticasone furoate inhalation powder) is a once-daily inhaled corticosteroid for the maintenance treatment of asthma.
Cerdelga
Aug 21, 2014 - Cerdelga (eliglustat) is a glucosylceramide synthase inhibitor indicated for the long-term treatment of adult patients with Gaucher disease type 1.
Jardiance
Aug 20, 2014 - Jardiance (empagliflozin) is a sodium glucose co-transporter-2 (SGLT2) inhibitor for the treatment of type 2 diabetes, and to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and heart disease.
Plegridy
Aug 18, 2014 - Plegridy (peginterferon beta-1a) is a pegylated interferon beta indicated for the treatment of patients with relapsing forms of multiple sclerosis.
Belsomra
Aug 13, 2014 - Suvorexant is a potential new insomnia drug which appears to help people fall asleep without causing next-day drowsiness.
Invokamet
Aug 11, 2014 - Invokamet (canagliflozin/metformin) is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor and biguanide combination for the treatment of type 2 diabetes.
Striverdi Respimat
Aug 8, 2014 - Striverdi Respimat (olodaterol) is a once-daily, long-acting beta-agonist (LABA) for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
Zydelig
Jul 24, 2014 - Zydelig (idelalisib) is a phosphoinositide 3-kinase (PI3K) delta inhibitor for the treatment of chronic lymphocytic leukemia, relapsed follicular B-cell non-Hodgkin lymphoma, and relapsed small lymphocytic lymphoma.
Targiniq ER
Jul 24, 2014 - Targiniq ER (naloxone and oxycodone) is a long-acting abuse-deterrent opioid analgesic formulation used to treat severe pain. Includes Targiniq ER side effects, interactions and indications.
Kerydin
Jul 16, 2014 - Kerydin (tavaborole) is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails.
Beleodaq
Jul 10, 2014 - Beleodaq (belinostat) is a histone deacetylase (HDAC) inhibitor for the treatment of peripheral T-cell lymphoma (PTCL).
Afrezza
Jun 30, 2014 - Afrezza (insulin human [rDNA origin]) Inhalation Powder is an ultra rapid-acting insulin for oral inhalation indicated for the treatment of adults with type 1 or type 2 diabetes mellitus.
Sivextro
Jun 25, 2014 - Sivextro (tedizolid phosphate) is an oxazolidinone antibiotic drug indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
Bunavail
Jun 24, 2014 - Bunavail (buprenorphine and naloxone) buccal film is an opioid analgesic/opioid antagonist formulation for the maintenance treatment of opioid dependence.
Jublia
Jun 10, 2014 - Jublia (efinaconazole) is a topical triazole antifungal for the treatment of onychomycosis of the toenails.
Omidria
Jun 9, 2014 - Omidria (ketorolac and phenylephrine) is an anti-inflammatory and mydriatic combination added to irrigation solution during cataract surgery and intraocular lens replacement procedures.
Dalvance
May 25, 2014 - Dalvance (dalbavancin) is a second generation, semi-synthetic lipoglycopeptide antibiotic for the
treatment of adult patients with complicated skin and skin structure infections, including those caused by
methicillin-resistant Staphylococcus aureus (MRSA).
Entyvio
May 20, 2014 - Entyvio (vedolizumab) is an integrin receptor antagonist for the treatment of Crohn's disease and ulcerative colitis.
Zontivity
May 8, 2014 - Zontivity (vorapaxar) is a protease-activated receptor-1 (PAR-1) antagonist for the prevention of cardiovascular events in high risk patients.
Incruse Ellipta
May 2, 2014 - Incruse Ellipta (umeclidinium) is an anticholinergic bronchodilator indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
Zykadia
Apr 30, 2014 - Zykadia (ceritinib) is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.
Sylvant
Apr 23, 2014 - Sylvant (siltuximab) is an interleukin-6 (IL-6) antagonist indicated for the treatment of patients with multicentric Castleman’s disease.
Cyramza
Apr 22, 2014 - Cyramza (ramucirumab) is a human vascular endothelial growth factor receptor 2
(VEGFR2) antagonist indicated for the treatment of gastric cancer, non-small cell lung cancer, colorectal cancer, and hepatocellular carcinoma.
Evzio
Apr 18, 2014 - Evzio (naloxone hydrochloride) is an opioid antagonist hand-held auto-injector indicated for the emergency treatment of known or suspected opioid overdose.
Tanzeum
Apr 15, 2014 - Tanzeum (albiglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes.
Zohydro ER
Apr 13, 2014 - Zohydro ER (hydrocodone) is a single-entity (without acetaminophen) extended-release opioid analgesic for around-the-clock management of moderate to severe chronic pain.
Otezla
Mar 23, 2014 - Otezla (apremilast) is a phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of psoriatic arthritis, plaque psoriasis, and oral ulcers associated with Behçet’s disease.
Impavido
Mar 20, 2014 - Impavido (miltefosine) is an oral alkylphosphocholine antiparasitic for the treatment of leishmaniasis.
Myalept
Feb 26, 2014 - Myalept (metreleptin) is a leptin analog
indicated to treat the complications of leptin deficiency in patients with
congenital or acquired generalized lipodystrophy.
Northera
Feb 19, 2014 - Northera (droxidopa) is an orally active synthetic precursor of norepinephrine indicated for the treatment of neurogenic orthostatic hypotension.
Vimizim
Feb 16, 2014 - Vimizim (elosufase alfa) is an enzyme replacement therapy for patients with Mucopolysaccharidosis Type IVA (Morquio A syndrome).
Hetlioz
Feb 2, 2014 - Hetlioz (tasimelteon) is a melatonin receptor agonist for the treatment of Non-24-Hour Disorder and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS).
Farxiga
Jan 8, 2014 - Farxiga (dapagliflozin) is an oral medication that may be given to certain people with diabetes, heart disease, or kidney disease to improve their outcomes. It belongs to the class of medicines known as selective sodium-glucose cotransporter-2 inhibitors.